Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;25(6):671-677.
doi: 10.1007/s11912-023-01395-4. Epub 2023 Mar 31.

Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma

Giuseppe Fotia  1 , Marco Stellato  2 , Valentina Guadalupi  1 , Pierangela Sepe  1 , Melanie Claps  1 , Patrizia Giannatempo  1 , Achille Bottiglieri  1 , Alessandro Rametta  1 , Ida Taglialatela  1 , Chiara Vela  1 , Giuseppe Procopio  1 , Elena Verzoni  1
Affiliations
Review

Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma

Giuseppe Fotia et al. Curr Oncol Rep. 2023 Jun.

Abstract

Purpose of review: In this review, we analyze the current state of research in development of new biomarkers that may be useful in managing metastatic renal cell carcinoma (mRCC) setting.

Recent findings: Combining tumor-based biomarkers (gene expression profile) and blood-based biomarkers (ctDNA, cytokines) would be helpful in acquiring information regarding RCC and might be significant in the decision-making process. Renal cell carcinoma (RCC) is the sixth most frequently diagnosed neoplasm in men and tithe in women, making it responsible for 5% and 3% of all diagnosed cancers respectively. Metastatic stage represents a non-negligible percentage at diagnosis and is characterized by poor prognosis. Despite clinical features and prognostic score could guide clinicians in therapeutic approach of this disease, biomarkers predictive of response to treatment remain an unmet need.

Keywords: Immuno-oncology; Metastatic renal cell carcinoma; Molecular signatures; Tumor biomarkers; VEGF-TKIs.

PubMed Disclaimer

References

    1. Lancet Oncol. 2022 May;23(5):612-624 - PubMed
    1. Nature. 2006 Mar 30;440(7084):692-6 - PubMed
    1. Ann Transl Med. 2020 Mar;8(6):269 - PubMed
    1. Lancet Oncol. 2013 Aug;14(9):901-8 - PubMed
    1. Nat Rev Cancer. 2019 Dec;19(12):698-715 - PubMed

Substances

LinkOut - more resources